These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 21196617

  • 1. Efficacy of low dose spironolactone in chronic kidney disease with resistant hypertension.
    Abolghasmi R, Taziki O.
    Saudi J Kidney Dis Transpl; 2011 Jan; 22(1):75-8. PubMed ID: 21196617
    [Abstract] [Full Text] [Related]

  • 2. Predictors of hyperkalemia risk following hypertension control with aldosterone blockade.
    Khosla N, Kalaitzidis R, Bakris GL.
    Am J Nephrol; 2009 Jan; 30(5):418-24. PubMed ID: 19738369
    [Abstract] [Full Text] [Related]

  • 3. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function.
    van den Meiracker AH, Baggen RG, Pauli S, Lindemans A, Vulto AG, Poldermans D, Boomsma F.
    J Hypertens; 2006 Nov; 24(11):2285-92. PubMed ID: 17053552
    [Abstract] [Full Text] [Related]

  • 4. The effect of low-dose spironolactone on resistant hypertension.
    Engbaek M, Hjerrild M, Hallas J, Jacobsen IA.
    J Am Soc Hypertens; 2010 Nov; 4(6):290-4. PubMed ID: 21130975
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease.
    Abe M, Okada K, Maruyama T, Matsumoto K.
    Pharmacotherapy; 2009 Sep; 29(9):1061-72. PubMed ID: 19698011
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Predictors of hyperkalemia risk after hypertension control with aldosterone blockade according to the presence or absence of chronic kidney disease.
    Gwoo S, Kim YN, Shin HS, Jung YS, Rim H.
    Nephron Clin Pract; 2014 Sep; 128(3-4):381-6. PubMed ID: 25572273
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Effect of renin-angiotensin-aldosterone system triple blockade on non-diabetic renal disease: addition of an aldosterone blocker, spironolactone, to combination treatment with an angiotensin-converting enzyme inhibitor and angiotensin II receptor blocker.
    Furumatsu Y, Nagasawa Y, Tomida K, Mikami S, Kaneko T, Okada N, Tsubakihara Y, Imai E, Shoji T.
    Hypertens Res; 2008 Jan; 31(1):59-67. PubMed ID: 18360019
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Does aldosterone-to-renin ratio predict the antihypertensive effect of the aldosterone antagonist spironolactone?
    Mahmud A, Mahgoub M, Hall M, Feely J.
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1631-5. PubMed ID: 16364838
    [Abstract] [Full Text] [Related]

  • 16. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension.
    Jamerson KA, Nwose O, Jean-Louis L, Schofield L, Purkayastha D, Baron M.
    Am J Hypertens; 2004 Jun; 17(6):495-501. PubMed ID: 15177521
    [Abstract] [Full Text] [Related]

  • 17. Patiromer to Enable Spironolactone Use in the Treatment of Patients with Resistant Hypertension and Chronic Kidney Disease: Rationale and Design of the AMBER Study.
    Agarwal R, Rossignol P, Garza D, Mayo MR, Warren S, Arthur S, Romero A, White WB, Williams B.
    Am J Nephrol; 2018 Jun; 48(3):172-180. PubMed ID: 30176673
    [Abstract] [Full Text] [Related]

  • 18. The effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study.
    Esnault VL, Brown EA, Apetrei E, Bagon J, Calvo C, DeChatel R, Holdaas H, Krcmery S, Kobalava Z, Amlodipine Versus Enalapril in Renal failure (AVER) Study Group.
    Clin Ther; 2008 Mar; 30(3):482-98. PubMed ID: 18405787
    [Abstract] [Full Text] [Related]

  • 19. Safety of the combination of valsartan and benazepril in patients with chronic renal disease. European Group for the Investigation of Valsartan in Chronic Renal Disease.
    Ruilope LM, Aldigier JC, Ponticelli C, Oddou-Stock P, Botteri F, Mann JF.
    J Hypertens; 2000 Jan; 18(1):89-95. PubMed ID: 10678548
    [Abstract] [Full Text] [Related]

  • 20. Intensive versus conventional therapy to slow the progression of idiopathic glomerular diseases.
    Bianchi S, Bigazzi R, Campese VM.
    Am J Kidney Dis; 2010 Apr; 55(4):671-81. PubMed ID: 20097461
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.